Researchers from the Department of Urology at The First Affiliated Hospital of Nanchang University and the Jiangxi Institute of Urology in Nanchang, China set out to construct a prognostic model to predict the cancer-specific survival (CSS) rate for patients with lymph-node positive bladder cancer. In their report, published in Frontiers in Oncology, they stated that they had constructed a prognostic nomogram that provided “an accurate individualized probability of cancer-specific survival in bladder cancer patients with lymph node-positive.”
The team included 2,050 patients diagnosed with lymph node-positive bladder cancer from the Surveillance Epidemiology and End Results (SEER) database. Patients were divided into a development cohort (n = 1,438) and a validation cohort (n = 612). Cox regression analysis was used to identify prognostic variables, and the CSS-predicting nomogram was constructed based on the indicated variables.
The variables used to develop the prognostic nomogram included summary stage, tumor size, chemotherapy, regional nodes examined, and positive lymph nodes. According to the researchers, the C-index of the nomogram was 0.716 in the development cohort and 0.691 in the validation cohort. Additionally, the receiver operating characteristic (ROC) was 0.803 at three years and 0.854 at five years in the development cohort, and 0.773 at three years and 0.809 at five years in the validation cohort.
The authors presented their nomogram as a validated prognostic model that could provide individualized prognostic predictions for patients with lymph node-positive bladder cancer. Overall, they suggested that “the nomogram could contribute to patient counseling, follow-up scheduling, and selection of treatment.”